Evidence map›Paper›PMID 36987403›Full record

SynthesisDrug design, development and therapy2023

Oliceridine for the Management of Moderate to Severe Acute Postoperative Pain: A Narrative Review.

Neil Daksla, Ashley Wang, Zhaosheng Jin, Abhishek Gupta, Sergio D Bergese

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Drug design, development and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 3 pooled it
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. The EDDrug design, development and therapy · 2026
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Neil DakslaDepartment of Anesthesiology, Stony Brook University Health Science Center, Stony Brook, NY, 11794-8480, USA.
Ashley WangDepartment of Anesthesiology, Stony Brook University Health Science Center, Stony Brook, NY, 11794-8480, USA.ORCID 0000-0001-6071-5778
Zhaosheng JinDepartment of Anesthesiology, Stony Brook University Health Science Center, Stony Brook, NY, 11794-8480, USA.
Abhishek GuptaDepartment of Anesthesiology, Stony Brook University Health Science Center, Stony Brook, NY, 11794-8480, USA.
Sergio D BergeseDepartment of Anesthesiology, Stony Brook University Health Science Center, Stony Brook, NY, 11794-8480, USA.ORCID 0000-0001-5641-5908
Stony Brook University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite current advances in acute postoperative pain management, prevalence remains high. Inadequate treatment could lead to poor outcomes and even progression to chronic pain. Opioids have traditionally been the mainstay for treatment of moderate to severe acute pain. However, their use has been associated with opioid-related adverse events (ORAEs), such as respiratory depression, sedation, nausea, vomiting, pruritus, and decreased bowel motility. In addition, their liberal use has been implicated in the current opioid epidemic. As a result, there has been renewed interest in multimodal analgesia to target different mechanisms of action in order to achieve a synergistic effect and minimize opioid usage. Oliceridine is a novel mu-opioid receptor agonist that is part of a new class of biased ligands that selectively activate G-protein signaling and downregulate β-arrestin recruitment. Since G-protein signaling has been associated with analgesia while β-arrestin recruitment has been associated with ORAEs, there is potential for a wider therapeutic window. In this review, we will discuss the clinical evidence behind oliceridine and its potential role in acute postoperative pain management. We have systematically searched the PubMed database using the keywords

Indexed as

Analgesics, OpioidMorphineGTP-Binding ProteinsHumansPostoperative PainSpiro CompoundsThiophenes((3-methoxythiophen-2-yl)methyl)((2-(9-(pyridin-2-yl)-6-oxaspiro(4.5)decan-9-yl)ethyl))amineAnalgesics, OpioidGTP-Binding ProteinsMorphineSpiro CompoundsThiophenesbiased agonismmultimodal analgesiaopioid-related adverse eventsopioidspostoperative pain

Identifiers

PMID36987403
PMCPMC10040154
OpenAlexW4353078214

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.